Home Cart Sign in  
Chemical Structure| 1702259-66-2 Chemical Structure| 1702259-66-2

Structure of H3B-6527
CAS No.: 1702259-66-2

Chemical Structure| 1702259-66-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

H3B-6527 is an orally active, highly selective, and covalent FGFR4 inhibitor with an IC50 of <1.2 nM. It inhibits FGFR1-3 with IC50 values of 320, 1290, and 1060 nM, respectively. H3B-6527 exhibits potent anticancer activity.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of H3B-6527

CAS No. :1702259-66-2
Formula : C29H34Cl2N8O4
M.W : 629.54
SMILES Code : C=CC(NC1=CC(N2CCN(CC)CC2)=CC=C1NC3=NC=NC(N(C)C(NC4=C(Cl)C(OC)=CC(OC)=C4Cl)=O)=C3)=O
MDL No. :MFCD30377210
InChI Key :MBWRLLRCTIYXDW-UHFFFAOYSA-N
Pubchem ID :118029202

Safety of H3B-6527

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of H3B-6527

RTK

Isoform Comparison

Biological Activity

Target
  • FGFR4

    FGFR4, IC50:<1.2 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
3T3 cells 0.1 nM –10 µM 5 days Evaluate the inhibitory effect of H3B-6527 on FGFR4 N535K and FGFR4 V550L, results showed that H3B-6527 was effective against FGFR4 N535K but not against FGFR4 V550L. PMC8285406
HN12 cells 5 μM Suppressed Vimentin protein levels, thereby inhibiting cell migration PMC7945659
KYSE150 1 μM 3 days Inhibited proliferation, invasion, and migration of KYSE150 cells, and altered epithelial-mesenchymal transition markers. PMC6275831
KYSE450 1 μM 3 days Inhibited proliferation, invasion, and migration of KYSE450 cells, and altered epithelial-mesenchymal transition markers. PMC6275831
CAMA1 1.0 µM 14 days H3B-6527 promoted the growth of FGF2-treated cells in FGFR1-amplified CAMA1 cells and inhibited FGF2-induced cell proliferation. PMC10979625
Human HepG2 cells 20 ng/mL 30 min To investigate the effect of FGFR4 inhibition on NPC1L1 protein degradation, results showed that H3B-6527 rescued FGF19-induced NPC1L1 protein decay. PMC9547418

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice Orthotopic tongue tumor model Intratumoral injection 10 μM(50 μl) Every 3 days for 2 weeks Evaluated the inhibitory effect of H3B-6527 on lymph node metastasis of MT-LE HN30 cells, showing that H3B-6527 significantly reduced lymph node metastasis PMC7945659
BALB/c nude mice Esophageal squamous cell carcinoma (ESCC) tumor xenograft model Intraperitoneal injection 10 mg/kg Once daily for 20 days H3B-6527 significantly inhibited the growth of ESCC xenograft tumors. PMC6275831
C57BL/6 mice Left ventricular hypertrophy model Intraperitoneal injection 10 mg/kg Daily until 12 weeks of age To evaluate the effect of H3B-6527 on left ventricular hypertrophy, the results showed that H3B-6527 did not improve left ventricular hypertrophy. PMC10762797
Mice NPC1L1hepatic-OE mice Intraperitoneal injection 5 mg/kg Once daily for 7 days To investigate the effect of H3B-6527 on hepatic NPC1L1 protein degradation in LD-fed mice, results showed that H3B-6527 partially restored bile cholesterol reabsorption efficiency. PMC9547418

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02834780 Advanced Hepatocellular Carcin... More >>oma|Hepatocellular Carcinoma|Liver Cancer|Liver Neoplasms|Hepatic Cancer|Hepatic Carcinoma Less << PHASE1 COMPLETED 2022-02-23 USC/Norris Comprehensive Cance... More >>r Center, Los Angeles, California, 90033, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, 92663, United States|UC Irvine Medical Center, Orange, California, 92868-3201, United States|UCLA Medical Center, Santa Monica, California, 90404, United States|Georgetown Unversity Lombardi Comprehensive Cancer Center, Washington, District of Columbia, 20007, United States|Northwestern Unversity, Chicago, Illinois, 60611, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|John theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Duke University Cancer Center, Durham, North Carolina, 27710, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, 45219, United States|University of Pennsylsvania - Perelman Cancer Center for Advanced Medicine, Philadelphia, Pennsylvania, 19104, United States|Simmons Comprehensive Cancer Center, Dallas, Texas, 75390, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|McGuire VA Medical Center, Richmond, Virginia, 23249, United States|UCL Cliniques universitaires Saint-Luc, Woluwe-Saint-Lambert, Brussels, 1200, Belgium|Universitair Ziekenhuis Gent, Gent, 9000, Belgium|Cross Cancer Institute, Edmonton, Alberta, T6G IZ2, Canada|Jurvanski Cancer Center, Hamilton, Ontario, L8V 5C2, Canada|Institut Bergonié, Bordeaux, 33076, France|Centre Oscar Lambret, Lille, 59000, France|H?pital Haut-Lévêque - CHU de Bordeaux, Pessac, 33604, France|Centre Eugène Marquis, Rennes, 35042, France|IRCCS Istituto Scientifico Romagnolo per lo studio e la cura dei tumori - U.O. di Oncologia Medica, Meldola, 47014, Italy|IRCCS Ospedale San Raffaele S.r.l. - PPDS, Milano, 20132, Italy|Azienda Ospedaliero Universitaria - Policlinico di Modena, Modena, 41124, Italy|Asan Medical Center, Seoul, 05505, Korea, Republic of|Altay Regional Oncology Center, Barnaul, Altay, Re, 656045, Russian Federation|Russian Oncology Research Center n a N N Blokhin, Moscow, 115478, Russian Federation|Omsk Regional Oncology Center, Omsk, 644046, Russian Federation|Railway Clinical Hospital JSC RZhD, Saint Petersburg, 195271, Russian Federation|City Clinical Oncology Dispensary, Saint Petersburg, 198255, Russian Federation|National University Cancer Insitute, Singapore, 119074, Singapore|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, 39008, Spain|Clínica Universidad de Navarra, Pamplona, Navarra, 31008, Spain|Hospital Universitario de Badajoz, Badajoz, 06080, Spain|Hospital Universitario Vall d'Hebron, Barcelona, 8035, Spain|General Universitario Gregorio Maranon, Madrid, 28007, Spain|START Madrid FJD, Hospital Universitario Fundacion Jimenez Diaz, Madrid, 28040, Spain|Hospital Universitario HM Sanchinarro, Madrid, 28050, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Taichung Veterans General Hospital, Taichung, 40705, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|Sarah Cannon Research Institute UK - SCRI - PPDS, London, W1G 6AD, United Kingdom Less <<
NCT03424577 Healthy Participants PHASE1 COMPLETED 2018-01-27 Worldwide Clinical Trials, San... More >> Antonio, Texas, 78217, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.59mL

0.32mL

0.16mL

7.94mL

1.59mL

0.79mL

15.88mL

3.18mL

1.59mL

References

 

Historical Records

Categories